QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.107.127357v1 323/3/759    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Joyeux-Faure, M. Search for Related Content PubMed PubMed Citation Articles by Joyeux-Faure, M.

PERSPECTIVES IN PHARMACOLOGY

Cellular Protection by Erythropoietin: New Therapeutic Implications?

INSERM, ERI17, Grenoble, France; and Université Grenoble 1, Facultéde Médecine, IFR1, Grenoble, France

Erythropoietin (EPO), the principal hematopoietic hormone produced by the kidney and the liver in fetuses, regulates mammalian erythropoiesis and exhibits diverse cellular effects in nonhematopoietic tissues. The introduction of recombinant human EPO (rhEPO) has marked a significant advance in the management of anemia associated with chronic renal failure. At the same time, experimental studies have unveiled its potential neuroprotective and cardioprotective properties, occurring independently of its hematopoietic action. As with other cytoprotective agents, administration of exogenous rhEPO can confer cerebral and myocardial protection against ischemia-reperfusion injury in terms of reduction in cellular apoptosis and necrosis, as well as improvement in functional recovery. Very recent studies even suggest that this drug could have beneficial applications in oncology, protecting against chemotherapy cardiotoxicity. The purpose of this letter is to review current information regarding the various conditions in which rhEPO and its derivates could confer cellular protection. We also address clinical perspectives and novel therapeutic strategies that could be developed based on these studies. Thus, EPO seems to be a very promising agent for protecting cellular survival during both acute and chronic diseases, and its future should be considered with enthusiasm.

Address correspondence to: Dr. Marie Joyeux-Faure, Laboratoire HP2, Université Grenoble 1, Institut Jean Roget, BP 170, 38042 Grenoble Cedex 9, France. E-mail: marie.faure{at}ujf-grenoble.fr

This article has been cited by other articles:

				C. Hudson, J. Hudson, M. Swaminathan, A. Shaw, M. Stafford-Smith, and U. D. Patel Emerging Concepts in Acute Kidney Injury Following Cardiac Surgery Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2008; 12(4): 320 - 330. [Abstract] [PDF]

				K. Ohori, T. Miura, M. Tanno, T. Miki, T. Sato, S. Ishikawa, Y. Horio, and K. Shimamoto Ser9 phosphorylation of mitochondrial GSK-3{beta} is a primary mechanism of cardiomyocyte protection by erythropoietin against oxidant-induced apoptosis Am J Physiol Heart Circ Physiol, November 1, 2008; 295(5): H2079 - H2086. [Abstract] [Full Text] [PDF]

				K. A. May and F. R. Khuri Unraveling the Mystery of Erythropoietin-Stimulating Agents in Cancer Promotion Cancer Res., June 1, 2008; 68(11): 4013 - 4017. [Abstract] [Full Text] [PDF]